FDA Adverse Event Injury Summary report: N

ACCESS® 2 IMMUNOASSAY SYSTEM

MDR report key: 2111647 · Received June 2, 2011

Report

Report Number
2122870-2011-01652
Event Type
Injury
Date Received
June 2, 2011
Date of Event
May 9, 2011
Report Date
May 9, 2011
Manufacturer
BECKMAN COULTER, INC.
Product Code
DHA
PMA / PMN Number
K922823/A007
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

THE CLASSIFICATION PRODUCT CODE OF THE SUSPECT MEDICAL DEVICE INVOLVED WAS INCORRECTLY IDENTIFIED AS CGN IN THE ORIGINAL 3500A. THE CORRECT CLASSIFICATION PRODUCT CODE IS JJE.

Additional Manufacturer Narrative · 1

SERVICE WAS NOT DISPATCHED FOR THIS EVENT. THE CUSTOMER SUSPECTED POSSIBLE SAMPLE INTERFERENCE AS A CONTRIBUTING CAUSE OF THIS EVENT AND WAS TO SUBMIT A SAMPLE TO BECKMAN COULTER INC. FOR INTERFERENCE TESTING. NO SAMPLE HAS BEEN RECEIVED TO DATE. A DEFINITIVE ROOT CAUSE FOR THIS EVENT HAS NOT BEEN DETERMINED TO DATE.

Description of Event or Problem · 1

THE CUSTOMER REPORTED THAT ON (B)(6) 2011 A HIGHER THAN EXPECTED HUMAN CHORIONIC GONADOTROPIN (BHCG) WAS GENERATED ON THE ACCESS 2 IMMUNOASSAY SYSTEM FOR ONE PATIENT SERUM SAMPLE. THE PATIENT HAS A HISTORY OF ELEVATED BHCG TESTS RESULTS. THE DETAILS, DATES AND PATIENT IMPACT SURROUNDING THESE PREVIOUS EVENTS ARE UNKNOWN. THE RESULT WAS REPORTED OUT OF THE LABORATORY. THE PATIENT UNDERWENT A PROCEDURE TO ASSESS FOR PREGNANCY BASED UPON THE ERRONEOUSLY ELEVATED BHCG RESULT. A URINE SAMPLE TEST ON 05/09/2011, ON THE SAME INSTRUMENT, GENERATED A LOWER BHCG VALUE THAT WAS CONSIDERED VALID. QUALITY CONTROL RESULTS WERE PERFORMING WITHIN CUSTOMER ESTABLISHED RANGES AT THE TIME OF THE EVENT. NO SYSTEM CHECK DATA WAS PROVIDED BY THE CUSTOMER.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ACCESS® 2 IMMUNOASSAY SYSTEM ANALYZER, CHEMISTRY (PHOTOMETRIC, DISCRETE), FOR CLINICAL USE DHA BECKMAN COULTER, INC. NA NA

Patients

Seq Age Sex Outcome Treatment
1 19 YR Required Intervention ACCESS TOTAL SSHCG